Skip to main content
. 2020 Oct 29;3(10):e2025109. doi: 10.1001/jamanetworkopen.2020.25109

Figure 3. Sensitivity Analyses Evaluating Association Between Tumor Mutational Burden (TMB) and OS Among Patients With All 10 Tumor Types.

Figure 3.

The study population was derived from patients tested by FoundationOne (F1) assay or F1 Companion Diagnostic (CDx) assay vs any FMI assay. OS was calculated from Foundation Medicine (FMI) report date vs date of first antineoplastic treatment. CGDB indicates clinicogenomic database; HR, hazard ratio; MSI-H, high microsatellite instability; TMB, tumor mutational burden; TMB-H, high TMB (≥10 or ≥13 mutations per megabase).